Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Average Target Price of $29.00

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $29.00.

KMTS has been the subject of a number of analyst reports. Evercore assumed coverage on Kestra Medical Technologies in a research report on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price target for the company. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company.

Insider Activity

In other news, insider Alfred Ford, Jr. sold 13,015 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.90, for a total value of $311,058.50. Following the completion of the sale, the insider directly owned 105,839 shares in the company, valued at approximately $2,529,552.10. The trade was a 10.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci Umberger sold 100,000 shares of the company’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the sale, the insider directly owned 195,825 shares of the company’s stock, valued at approximately $5,322,523.50. This represents a 33.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 399,694 shares of company stock worth $10,842,727. 5.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors have recently made changes to their positions in the business. Sei Investments Co. boosted its stake in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after buying an additional 5,731 shares during the last quarter. Bank of New York Mellon Corp increased its position in Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after buying an additional 22,471 shares during the period. Corient Private Wealth LP increased its position in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after buying an additional 44,839 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $603,000.

Kestra Medical Technologies Stock Performance

KMTS stock opened at $30.61 on Tuesday. Kestra Medical Technologies has a 1 year low of $17.34 and a 1 year high of $31.04. The company has a fifty day simple moving average of $26.64 and a 200 day simple moving average of $23.79. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The business had revenue of $30.97 million for the quarter. As a group, research analysts expect that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.